Skip to main content
SAB Biotherapeutics, Inc. (SABS)
NASDAQ: SABS · Real-Time Price · USD
3.840
+0.050 (1.32%)
Mar 9, 2026, 3:42 PM EDT - Market open

SAB Biotherapeutics Revenue

SAB Biotherapeutics had revenue of $114.70K in the twelve months ending September 30, 2025, down -92.42% year-over-year. In the year 2024, SAB Biotherapeutics had annual revenue of $1.32M, down -40.94%.

Revenue (ttm)
$114.70K
Revenue Growth
-92.42%
P/S Ratio
1,587.61
Revenue / Employee
$1,821
Employees
63
Market Cap
182.81M

Revenue Chart

History

Fiscal Year End Revenue Change Growth
Dec 31, 20241.32M-916.58K-40.94%
Dec 31, 20232.24M-21.67M-90.63%
Dec 31, 202223.90M-36.97M-60.73%
Dec 31, 202160.88M5.64M10.21%
Dec 31, 202055.24M51.80M1,504.91%
Dec 31, 2019 Pro Pro Pro

Revenue Definition

Revenue, also called sales, is the amount of money a company receives from its business activities, such as sales of products or services. Revenue does not take any expenses into account and is therefore different from profits.

Full Definition

Related Stocks

Company Name Revenue
Heron Therapeutics 154.90M
Vaxart 148.20M
ProQR Therapeutics 18.86M
Whitehawk Therapeutics 14.38M
Cartesian Therapeutics 1.09M
Molecular Partners AG 856.30K
NeOnc Technologies Holdings 59.99K
Revenue Rankings

SABS News

More News